vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and STAG Industrial, Inc. (STAG). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($268.1M vs $224.2M, roughly 1.2× STAG Industrial, Inc.). STAG Industrial, Inc. runs the higher net margin — 27.6% vs 1.4%, a 26.3% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.7% vs 9.1%). Over the past eight quarters, STAG Industrial, Inc.'s revenue compounded faster (8.7% CAGR vs 5.3%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Stag Arms is a firearms manufacturer founded in May 2003 and located in Cheyenne, Wyoming. Stag Arms is a manufacturer of the AR-15 type rifle, marketed as Stag-15 rifles. Stag advertises that all their weapons and accessories are made in the United States. They are best known for their left-handed AR-15 rifles, which use a mirror imaged upper receiver and have the ejection port reversed for left-handed shooters and the safety selector control on the right side of the lower receiver.
ACAD vs STAG — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $268.1M | $224.2M |
| Net Profit | $3.6M | $62.0M |
| Gross Margin | — | — |
| Operating Margin | -1.7% | — |
| Net Margin | 1.4% | 27.6% |
| Revenue YoY | 9.7% | 9.1% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.02 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $268.1M | $224.2M | ||
| Q4 25 | $284.0M | $220.9M | ||
| Q3 25 | $278.6M | $211.1M | ||
| Q2 25 | $264.6M | $207.6M | ||
| Q1 25 | $244.3M | $205.6M | ||
| Q4 24 | $259.6M | $199.3M | ||
| Q3 24 | $250.4M | $190.7M | ||
| Q2 24 | $242.0M | $189.8M |
| Q1 26 | $3.6M | $62.0M | ||
| Q4 25 | $273.6M | $83.5M | ||
| Q3 25 | $71.8M | $48.6M | ||
| Q2 25 | $26.7M | $50.0M | ||
| Q1 25 | $19.0M | $91.4M | ||
| Q4 24 | $143.7M | $51.0M | ||
| Q3 24 | $32.8M | $41.9M | ||
| Q2 24 | $33.4M | $59.8M |
| Q1 26 | — | — | ||
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — |
| Q1 26 | -1.7% | — | ||
| Q4 25 | 6.1% | — | ||
| Q3 25 | 12.8% | — | ||
| Q2 25 | 12.2% | — | ||
| Q1 25 | 7.9% | — | ||
| Q4 24 | 59.1% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 12.6% | — |
| Q1 26 | 1.4% | 27.6% | ||
| Q4 25 | 96.3% | 37.8% | ||
| Q3 25 | 25.8% | 23.0% | ||
| Q2 25 | 10.1% | 24.1% | ||
| Q1 25 | 7.8% | 44.5% | ||
| Q4 24 | 55.4% | 25.6% | ||
| Q3 24 | 13.1% | 21.9% | ||
| Q2 24 | 13.8% | 31.5% |
| Q1 26 | $0.02 | $0.32 | ||
| Q4 25 | $1.61 | — | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.16 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | — | ||
| Q2 24 | $0.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $8.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $3.6B |
| Total Assets | $1.6B | $7.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $8.9M | ||
| Q4 25 | $177.7M | $14.9M | ||
| Q3 25 | $258.0M | $17.3M | ||
| Q2 25 | $253.6M | $15.4M | ||
| Q1 25 | $217.7M | $9.3M | ||
| Q4 24 | $319.6M | $36.3M | ||
| Q3 24 | $155.1M | $70.0M | ||
| Q2 24 | $177.1M | $33.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $3.1B | ||
| Q2 25 | — | $3.0B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | — | $2.9B | ||
| Q2 24 | — | $2.8B |
| Q1 26 | — | $3.6B | ||
| Q4 25 | $1.2B | $3.6B | ||
| Q3 25 | $917.3M | $3.4B | ||
| Q2 25 | $822.4M | $3.4B | ||
| Q1 25 | $765.2M | $3.5B | ||
| Q4 24 | $732.8M | $3.5B | ||
| Q3 24 | $577.2M | $3.3B | ||
| Q2 24 | $516.7M | $3.3B |
| Q1 26 | $1.6B | $7.2B | ||
| Q4 25 | $1.6B | $7.2B | ||
| Q3 25 | $1.3B | $6.9B | ||
| Q2 25 | $1.2B | $6.8B | ||
| Q1 25 | $1.1B | $6.8B | ||
| Q4 24 | $1.2B | $6.8B | ||
| Q3 24 | $976.9M | $6.6B | ||
| Q2 24 | $914.1M | $6.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.91× | ||
| Q3 25 | — | 0.91× | ||
| Q2 25 | — | 0.88× | ||
| Q1 25 | — | 0.87× | ||
| Q4 24 | — | 0.88× | ||
| Q3 24 | — | 0.89× | ||
| Q2 24 | — | 0.84× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
